E1: initial reporter address: (b)(6).Prismaflex st100 set c has been temporarily approved for use in the us under emergency use authorization eua(b)(4).To deliver crrt to treat patients in an acute care environment during the covid-19 pandemic.H10: the actual device was not available; however, a photograph of the sample was provided for evaluation.During visual inspection of the provided photographic samples, the return line was observed disconnected from the screwed connector.Additionally, there is a non-homogeneous mark of solvent observed on the tubing.The reported condition was verified.The cause of the condition was due to the lack of solvent applied during the assembly phase of manufacturing.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.Should additional relevant information become available, a supplemental report will be submitted.
|